Publications by authors named "D Planas"
Article Synopsis
- - First-generation monoclonal antibodies (mAbs) for COVID-19 were withdrawn due to resistance from Omicron variants, but two new mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved in 2024.
- - Researchers tested these mAbs against contemporary JN.1 sublineages and found VYD222 still had moderate activity, but AZD3152 lost effectiveness against several variants.
- - The study underscores the importance of monitoring VYD222's clinical performance and raises concerns about AZD3152's efficacy in treating infections from newer variants.
The mechanistic target of rapamycin (mTOR) positively regulates multiple steps of the HIV-1 replication cycle. We previously reported that a 12-week supplementation of antiretroviral therapy (ART) with metformin, an indirect mTOR inhibitor used in type-2 diabetes treatment, reduced mTOR activation and HIV transcription in colon-infiltrating CD4 T cells, together with systemic inflammation in nondiabetic people with HIV-1 (PWH). Herein, we investigated the antiviral mechanisms of metformin.
View Article and Find Full Text PDFPredicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion.
View Article and Find Full Text PDFArticle Synopsis
- Antibodies are crucial for defense against SARS-CoV-2, but their effectiveness is threatened by new viral variants.
- Two specific broadly neutralizing antibodies, Cv2.3194 and Cv2.3132, were identified from the memory B cells of an individual who recovered from the original SARS-CoV-2 infection.
- When used together, these antibodies exhibit a synergistic effect that enhances their ability to neutralize SARS-CoV-2, indicating that strong immune responses from previous infections can still be effective against evolving virus strains.